Abstract
This case highlights that hybrid 18F-FDG PET/MR imaging could play a key role in the screening for Lynch syndrome (LS) in endometrial carcinoma (EC) patients. By providing simultaneous metabolic and high-resolution anatomical data, PET/MR can identify synchronous primary tumors that might be missed by standard clinical criteria.
Introduction
Lynch syndrome is an autosomal dominant condition caused by germline mutations in mismatch repair (MMR) genes, significantly increasing the risk of colorectal and endometrial carcinomas. In many women, EC acts as a "sentinel" malignancy, appearing years before a colorectal diagnosis. However, traditional screening methods like the Amsterdam II or revised Bethesda criteria—which rely heavily on family history and age—miss a significant portion of LS-related cases. There is a critical need for non-invasive diagnostic tools to identify synchronous tumors and trigger appropriate genetic testing.
Case Presentation
A 63-year-old female presented with postmenopausal bleeding. Initial diagnostic workup, including transvaginal ultrasonography and endometrial cytology, suggested endometrial malignancy. Tumor markers (CA125, CEA, CA19-9) were within normal ranges. Given the patient's age and lack of relevant family history, she did not meet the standard clinical criteria for Lynch syndrome suspicion.
Imaging and Incidental Findings
To further evaluate the extent of the disease, the patient underwent hybrid 18F-fluorodeoxyglucose (18F-FDG) PET/MR imaging. The scan revealed a polypoid mass in the lower uterine segment with a maximum standardized uptake value (SUVmax) of 5.7. Notably, the whole-body PET component identified a highly metabolic area in the descending colon (SUVmax 17.68), which the MR component localized to a thickened intestinal wall.
The discovery of this synchronous colon mass prompted a colonoscopy and biopsy, which confirmed a poorly differentiated tubular adenocarcinoma.
Molecular and Genetic Analysis
Post-operative histopathology confirmed G2 endometrial carcinoma with superficial myometrial invasion. Immunohistochemistry (IHC) of the tumor tissue showed a loss of MLH1 and PMS2 protein expression, indicating a mismatch repair deficiency. Subsequent genetic testing revealed deletion mutations in exons 16 and 17 of the MLH1 gene, alongside mutations in MSH2 and MSH6, confirming the diagnosis of Lynch syndrome.
Discussion
This case underscores two critical clinical "red flags" for Lynch syndrome. First, the anatomical location of the EC in the lower uterine segment is highly suggestive of LS, as this site accounts for only a small fraction of sporadic EC cases. Second, the use of hybrid PET/MR allowed for the incidental detection of a synchronous colorectal primary in a patient who did not fit the traditional profile for hereditary cancer screening.
Compared to PET/CT, PET/MR offers superior soft-tissue contrast, which is essential for staging pelvic malignancies and identifying subtle structural abnormalities in the bowel wall. The metabolic data provided by the PET component is invaluable for flagging synchronous lesions that might otherwise remain asymptomatic.
Conclusion
Hybrid 18F-FDG PET/MR imaging is a powerful, non-invasive tool that can facilitate the early diagnosis of Lynch syndrome by identifying synchronous primary tumors. Incorporating PET/MR into the diagnostic workflow for EC patients, particularly those with tumors in the lower uterine segment, could significantly improve the detection of hereditary cancer syndromes and lead to more personalized patient management and family screening.
Summary updated